Colossal Biosciences

Colossal Biosciences, founded with the mission to leverage genetic engineering for de-extinction, aims to revive species like the woolly mammoth, Tasmanian tiger, and dodo. The company envisions reintroducing these species into their natural habitats to restore ecological balance. Their primary focus is on developing hybrid calves of the woolly mammoth by 2028 and launching a thylacine research project to release Tasmanian tiger joeys in Australia. Colossal's innovative approach combines cutting-edge biotechnology with conservation efforts.

Notable figures associated with Colossal Biosciences include prominent geneticists and conservationists who bring expertise and credibility to their ambitious projects. The company has garnered significant attention and investment from leading venture capitalists and biotech investors, underscoring its potential impact. Key achievements include advancements in genetic engineering techniques and successful initial phases of their de-extinction projects. Colossal Biosciences aims to make a profound ecological impact by reviving extinct species and promoting biodiversity.